Advocacy Actions
Lobby Letter to PBOC on the Carbon Emission Reduction Facility Framework
On Nov 29th, European Union Chamber of Commerce in China (EUCCC) and the European Banking Federation (EBF) sent a lobby letter to PBOC regarding the carbon emission reduction facility framework.
Read moreSubmission of Comments on Draft Measures on Security Assessment of the Cross-border Transfer of Data
At the end of October, the Cybersecurity Administration of China (CAC) published a invitation to public consultation on the Measures on Security Assessment of the Cross-border Transfer of Data (Draft for comments).
Read moreComments to National Health Commission (NHC) on the Regulatory Measures of Internet-based Diagnosis and Treatment (Draft for Comment)
On 25th November, European Chamber Pharmaceutical Working Group submitted comments to National Health Commission (NHC) on the Regulatory Measures of Internet-based Diagnosis and Treatment (Draft for Comment).
Read moreMeeting with Ms. Zhu Yi, Deputy Director General of Shanghai Commerce Commission
Vice President Bettina Schoen briefed DDG Zhu the General Business Outlook, current challenges facing my European companies and the key recommendations in the position paper, as well as appreciated all the support from SCOFCOM to our member companies in the past year.
European Chamber President Meets with HR/VP Josep Borrell
On the 25th November, European Chamber President Joerg Wuttke met with High Representative for Foreign Affairs/Vice-President Josep Borrell.
Read moreMeeting with Mr. XUE Feng, Director of Shanghai Foreign Investment Development Board( Invest Shanghai)
The European Chamber Shanghai Chapter met with Mr. XUE Feng, Director of Shanghai Foreign Investment Development Board (Invest Shanghai) to present the 2021 European Chamber 2021/2022 Position Paper
Read moreEuropean Chamber President participates in the EU-China CEO and Former Senior Officials Dialogue
On the 23rd November European Chamber President Joerg Wuttke participated in the EU-China CEO and Former Senior Officials Dialogue.
Read moreMeeting with Jiangsu Development and Reform Commission (Jiangsu Energy Bureau)
On 22nd November 2021, the European Chamber Shanghai and Nanjing Chapters jointly hosted an online meeting with the Jiangsu Development and Reform Commission (Energy Bureau of Jiangsu) focused on the policy interpretation of the ‘dual control’ energy strategy and its overarching impact on the business landscape for foreign investment.
Key concerns raised from the National Vice Chair of the Energy Working Group focused on industry efficiency benchmarks issued last week by the NDRC, including the potential timeline for the launch of the benchmark and whether companies would continue to face issues on total energy consumption. Further comments from the European business community were made outlining the negative impact of this year’s power shortages on the investment confidence from European HQs, and opportunities regarding green power investment and concerns over long-term access to green energy.
The Deputy Director General of the Jiangsu Development and Reform Commission (Jiangsu Energy Bureau) reiterated that prior notice would be provided for future power cuts to enable member companies to make arrangements in advance, while energy-intensive industries would be prioritised for the implementation of the industry benchmarks. Jiangsu provincial government leaders also stressed the importance of stabilising foreign investment by mitigating the power shortages and building on the foundation for energy development in Jiangsu.
Comments to National People's Congress (NPC) on the Anti-monopoly Law of the People's Republic of China (Draft Amendments)
The European Chamber submitted comments to National People's Congress (NPC) on the Anti-monopoly Law of the People's Republic of China (Draft Amendments) on 19th November.
Read moreComments to Center for Drug Evaluation (CDE) on the Code of Practice for Managing the Suspension and Resumption of Review Timing in NMPA’s Drug Review Process (Trial) (Draft for comment)
On 17th November, the European Chamber Pharmaceutical Working Group submitted comments to Center for Drug Evaluation (CDE) on the Code of Practice for Managing the Suspension and Resumption of Review Timing in NMPA’s Drug Review Process (Trial) (Draft for comment).
Read more